Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis
ANX-LA
2 other identifiers
interventional
110
1 country
1
Brief Summary
The purpose of this study is to determine the impact on anxiety between patients with a period of care support following their announcement of an acute leukemia (AL) diagnosis and patients without this accompaniment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 24, 2026
CompletedFirst Posted
Study publicly available on registry
March 30, 2026
CompletedStudy Start
First participant enrolled
March 30, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 15, 2029
April 29, 2026
March 1, 2026
3 years
March 24, 2026
April 24, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Anxiety improvment
variation of anxiety level using STAI questionnaire
7 days after diagnosis announcement
Study Arms (2)
Standard arm
NO INTERVENTIONAfter randomization and diagnosis announcement, patient will be followed as usually
Experimental arm
EXPERIMENTALAfter randomization and diagnosis announcement, patient will have dedicated time with a nurse to explain in detail the diagnosis, the treatment. The anxiety will be also evaluated at different timepoints
Interventions
a dedicated time with a specialized nurse in announcement will be given tot the patient. The anxiety will also be evaluated
Eligibility Criteria
You may qualify if:
- informed consent signed
- medical confirmation of acute leukemia diagnosis
- age equal of superior to 26 years and under 80 years
- confirmed diagnosis not yet treated
- hospitalization at Centre Henri Becquerel
- member or beneficiary of a social security
You may not qualify if:
- Patient unable to understand the study for any reason or to comply with the trial's requirements
- Patient in relapse of acute leukemia
- Patient diagnosed with acute myeloid leukemia 3
- History of cancer within the 5 years preceding the year of study enrollment
- Alcohol and drug abuse
- Diagnosed psychiatric illness
- Patient under guardianship, curatorship, or legal protection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre Henri Becquerel
Rouen, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Fabrice Jardin, Md PhD
Centre Henri Becquerel
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 24, 2026
First Posted
March 30, 2026
Study Start
March 30, 2026
Primary Completion (Estimated)
March 30, 2029
Study Completion (Estimated)
April 15, 2029
Last Updated
April 29, 2026
Record last verified: 2026-03